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Abstract
Background—Little is known about the etiology of nonsyndromic microtia. This study 
investigated the hypothesis that microtia is caused by vascular disruption.
Methods—The study analyzed data from the population-based National Birth Defects Prevention 
Study (NBDPS) for deliveries between 1997 and 2005. Four hundred eleven nonsyndromic cases 
of microtia, with or without additional defects, were compared to 6560 nonmalformed infants with 
respect to maternal exposures to vasoactive medications and smoking during the periconceptional 
period and conditions that have previously been associated with vascular events (multiple 
gestation, maternal history of type 1, type 2, or gestational diabetes, and hypertension). Odds 
ratios (ORs) were estimated with multivariable models, controlling for the effects of race/
ethnicity, education, periconceptional folic acid use, and study center.
Results—Risk estimates for vasoactive medications and smoking were not meaningfully 
increased. Maternal type 1/2 diabetes was diagnosed before or during the index pregnancy in 4% 
and 1% of cases, respectively, compared to 1% and 0.05% of controls; the adjusted OR for these 
two groups combined was 7.2 (95% confidence interval [CI], 3.9–13.1). Gestational diabetes was 
observed for 9% of cases and 6% of controls; the OR was moderately elevated (OR, 1.4; 95% CI, 
0.9–2.0). ORs were also increased for multiple gestations (OR, 2.5; 95% CI, 1.5–4.2) and pre-
existing hypertension (OR, 1.6; 95% CI, 1.0–2.5).
Conclusions—Because ORs were only elevated for diabetes and not for vasoactive exposures or 
other potential vascular events, findings suggest that some microtia occurrences may be part of the 
diabetic embryopathy rather than manifestations of vascular disruption.
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Introduction
Microtia is a birth defect of the external ear that can vary in presentation from minor 
changes in the external ear's size or structure to its most severe form, anotia, in which the 
external ear and auditory canal are absent. It may present as an isolated defect or with other 
defects and is also a component of several syndromes including Goldenhar, Treacher 
Collins, and Nager (Harris et al., 1996; Alasti and Van Camp, 2009).
Descriptive epidemiologic studies have reported associations between microtia and older 
maternal age (Harris et al., 1996; Forrester and Merz, 2005; Canfield et al., 2009), lower 
maternal educational attainment (Shaw et al., 2004; Husain et al., 2008; Canfield et al., 
2009), multiple births (Shaw et al., 2004; Forrester and Merz, 2005), and male infant sex 
(Harris et al., 1996; Shaw et al., 2004; Forrester and Merz, 2005; Canfield et al., 2009). 
Previous studies have found that compared to non-Hispanic whites, Hispanics (Harris et al., 
1996; Shaw et al., 2004; Husain et al., 2008; Canfield et al., 2009) and Asians (Harris et al., 
1996; Forrester and Merz, 2005) have increased risk, and non-Hispanic blacks (Husain et al., 
2008; Canfield et al., 2009) have lower risk. Several studies, including one that examined 
earlier data from the same source used in our study, have reported an association between 
microtia and maternal diabetes (Mastroiacovo et al., 1995; Wang et al., 2002; Correa et al., 
2008).
Single gene defects and chromosomal abnormalities have been identified for several 
syndromes that include microtia, such as Townes–Brocks, branchio-oto-renal, and DiGeorge 
(Alasti and Van Camp, 2009; Luquetti et al., 2011), but much remains unknown about the 
etiology of nonsyndromic occurrences of this malformation. Several hypotheses have been 
proposed, however. One causal mechanism hypothesizes that the neural crest cell formation, 
migration, and proliferation necessary for normal development of the ear are altered by one 
or more factors (Johnston et al., 1990; Luquetti et al., 2011). Wang et al. (2002) proposed 
that maternal diabetes may be one such factor. Castilla et al. (1999) proposed that chronic 
hypoxia observed among mothers living at high altitude may be another. Lammer et al. 
(1985) proposed that retinoic acid may cause deficiencies in the cephalic neural crest cells 
resulting in the retinoic acid embryopathy, which includes microtia and other craniofacial 
defects, as well as defects of the heart, thymus, and central nervous system.
Another potential causal mechanism is vascular disruption, a mechanism that also has been 
proposed for several other birth defects (Van Allen, 1981). Animal (Newman and 
Hendrickx, 1981; Escobar and Liechty, 1998) and clinical (Hoyme et al., 1981; Vargas et 
al., 2000; Werler et al., 2004a; Werler et al., 2009) studies offer support for this causal 
mechanism for a variety of birth defects. Vasoactive exposures considered in studies that 
tested the vascular disruption hypothesis include medications and illicit drugs with 
vasodilatory or vasoconstrictive properties (Martin et al., 1992; Werler et al., 2004a; Werler 
et al., 2009) and cigarette smoking, which is mildly vasoconstrictive (Werler et al., 2003; 
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Werler et al., 2004a). Conditions that might be markers of vascular events such as diabetes, 
hypertension, and multiple gestations have also been studied in association with various 
purported vascular disruption defects (Lawson et al., 2002; Werler et al., 2004a; Verona et 
al., 2006; Husain et al., 2008). However, other than a study by Lawson et al. (2002) that 
observed an association between multiple gestations and microtia, studies have not explored 
microtia as a vascular disruption defect. In this study, we examined the associations between 
maternal vasoactive exposures and possible vascular events and the risk for microtia.
Methods
We analyzed data collected by the National Birth Defects Prevention Study (NBDPS), an 
ongoing, multisite, population-based, case-control study of environmental and genetic risk 
factors associated with selected major structural birth defects (Yoon et al., 2001). Birth 
defects surveillance systems in 10 states in the United States (Arkansas, California, Georgia, 
Iowa, Massachusetts, New Jersey [ending in 2002], New York, North Carolina [beginning in 
2003], Texas, and Utah [beginning in 2003]) ascertain case infants using standardized, 
detailed case definitions of over 30 defects and report them to the NBDPS. Each site also 
identifies a random sample of nonmalformed control infants from birth certificates or birth 
hospital data for the same geographic regions and time periods as case infants. Mothers of 
case and control infants who agree to participate are contacted within 24 months after their 
estimated date of delivery (EDD). Using a computer-assisted telephone interview in English 
or Spanish, trained interviewers collect information on family demographics, maternal 
medical history, pregnancy history, and behaviors. When mothers report a specific illness or 
condition (e.g., hypertension, fever), they are asked about medications taken for this illness. 
They are also read a list of specific medications and asked about the use of each; they are 
also asked about their use of illicit drugs, including specific questions on cocaine, crack, and 
amphetamines. Drugs are coded using the Boston University Slone Epidemiology Center 
Drug Dictionary (Kelley et al., 2003). For this analysis, we included information from 
mothers with delivery dates between October 1, 1997, and December 31, 2005. The 
institutional review boards for each site approved the NBDPS protocol.
Outcome
Information abstracted from medical records for case infants is reviewed by a clinical 
geneticist who first ensures that each case meets the predefined diagnostic criteria and then 
classifies the occurrence of birth defects in each case as either “isolated” (i.e., microtia 
occurring in isolation, with other minor anomalies, or with major structural anomalies 
presumed to be secondary to a shared primary defect) or “multiple” (i.e., microtia occurring 
with other presumably unrelated major structural defects). Details of this review have been 
described previously (Rasmussen et al., 2003). For this analysis, cases classified as isolated 
and multiple comprised the case group. Infants whose microtia was part of the 
oculoauriculovertebral spectrum (OAVS), which includes ear as well as eye, craniofacial, or 
vertebral defects, were classified as isolated or multiple based on the non-ear structural 
defects using the schema above. Infants with known chromosomal abnormalities or single-
gene disorders are excluded from NBDPS.
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We considered two categories of maternal vasoactive exposures, medications and cigarette 
smoking, and three categories of potential vascular events, diabetes, hypertension, and 
multiple gestation. The time period of interest for medication and smoking exposures was 1 
month before conception through the third month of pregnancy. We identified any use of 
medications with vasoactive properties including decongestants, antimigraine triptans and 
ergots, amphetamines, cocaine, bronchodilators, antihypertensives, and nonsteroidal anti-
inflammatory drugs; exposures to both single component and multicomponent medications 
were included. Cigarette smoking was classified according to the number of cigarettes 
smoked per day in the exposure period (no smoking, 1–14 cigarettes per day, ≥15 cigarettes 
per day). Diabetes was classified according to its type and the timing of diagnosis, resulting 
in four groups: no diabetes, type 1 or type 2 diabetes diagnosed before the index pregnancy, 
type 1 or type 2 diabetes diagnosed during the index pregnancy, and gestational diabetes; 
subsequently type 1 and type 2 diabetes are combined and referred to as “diabetes.” 
Although mothers who report diabetes are asked about the type of diabetes they have and are 
read a list of specific types, we were concerned that some mothers who reported diabetes 
diagnosed during pregnancy may, in fact, have had gestational diabetes. We therefore 
reviewed the interview records for these women and determined that all but one reported 
being diagnosed within the first 2 months of pregnancy, suggesting that this was not 
gestational diabetes, but likely pre-existing diabetes that was undiagnosed until pregnancy 
onset. The number of women with diabetes diagnosed during pregnancy was small, 
prompting us to combine these women with those diagnosed before the index pregnancy. 
Hypertension was classified according to the timing of the diagnosis, resulting in three 
groups: no hypertension, hypertension diagnosed before the index pregnancy, and 
hypertension diagnosed during the index pregnancy. For plurality, pregnancies were 
classified as single or multiple gestations.
Statistical Analysis
We calculated crude and adjusted odds ratios (aORs) and 95% confidence intervals (CIs) for 
the associations between the purported vasoactive exposures and the occurrence of microtia 
using a multivariable logistic regression model with terms for each of the exposures. For 
adjusted analyses, we examined the following potential confounders: maternal age at 
delivery (<20 years, 20–29 years, ≥30 years), binge alcohol use during the month before or 
the first 3 months of pregnancy (>4 drinks in one sitting; alcohol use, but not binge use; no 
use), pre-pregnancy body mass index (BMI; underweight, <18.5 kg/m2; normal weight, 
18.5–<25 kg/m2; overweight, 25–<30 kg/m2; obese, ≥30 kg/m2), education (<12 years, 12 
years, ≥13 years), race/ethnicity (non-Hispanic white, non-Hispanic black, Hispanic, other), 
folic acid use 1 month before conception through month 1 of pregnancy (any, none), infant 
sex (male, female, other/missing), number of previous live births (0, ≥1), study site, intent to 
become pregnant (yes/did not care, no), and year of infant's birth. Those that changed any of 
the estimated associations for the main effects by 10% or more were included in the adjusted 
analyses; these were education, race/ethnicity, periconceptional folic acid use, and study 
center. Separate analyses were conducted for any microtia (defined as occurrence of 
microtia as an isolated or multiple defect) and for isolated microtia. Because interviews were 
conducted up to 2 years after the EDD, we were concerned that as the time to interview 
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increased, errors in the reporting of exposures would increase. We were especially 
concerned that errors would be more common among control mothers than case mothers, 
which would result in biased odds ratios (ORs) among those with longer intervals to the 
interview. To address this issue of recall error, we also estimated the main effects stratified 
by the time from EDD to the interview date (<1 year from EDD vs. ≥1 year). All analyses 
were conducted with the statistical software package SPSS version 16.0.
Results
The case group was comprised of 423 infants diagnosed with microtia; 306 (72%) had 
isolated microtia and 117 (28%) had multiple defects. The control group was comprised of 
6807 nonmalformed infants. We excluded two case infants (both had isolated defects) and 
60 control infants because their mothers did not complete the medication section of the 
interview. Our final sample included 421 case infants (304 with isolated defects) and 6747 
control infants. The distributions of maternal characteristics for both cases and controls are 
provided in Table 1. Compared to mothers of control infants, mothers of infants in both the 
any microtia and isolated microtia case groups were less likely to be of non-Hispanic white 
race/ethnicity, to have 12 or more years of education, to have higher household incomes, to 
be born in the United States, and to have used periconceptional folic acid.
Among the mothers of case infants, there were no exposures to triptans or ergots from the 
month before pregnancy through the third month of pregnancy. Because only two case 
mothers (0.5%) and 40 control mothers (0.6%) reported taking amphetamines during the 
time period of interest, we did not include this exposure as a term in our models (data not 
shown). Table 2 presents the distributions for the other vasoactive exposures and markers of 
vascular events for cases and controls and aORs and 95% CIs. For this analysis, we included 
those with complete covariate data: 411 cases with any microtia (97.2% of eligible cases) 
and 6560 controls (96.4% of eligible controls); 296 of the cases were classified as isolated 
and 115 as multiple. Compared with control mothers, mothers of case infants were more 
likely to have diabetes (among case mothers with diabetes, 60% reported having type 1 
diabetes and 40% reported having type 2 diabetes; among control mothers, these proportions 
were 45% and 55%, respectively). Nevertheless, it is important to note that the number of 
mothers with these conditions was small (4.9% of cases and 0.6% of controls); 3.9% of case 
mothers were diagnosed before the index pregnancy compared to 0.6% of control mothers, 
and 1.0% of case mothers were diagnosed during the index pregnancy compared to 0.05% of 
control mothers. For the occurrence of any microtia, we observed an aOR of 7.2 (95% CI, 
3.9–13.1) for diabetes diagnosed before or during the index pregnancy. For gestational 
diabetes, the aOR was 1.4 (95% CI, 0.9–2.0). Although most of the infants of mothers with 
diabetes had multiple defects, the aOR also was elevated when we included only infants 
with isolated microtia: aORs were 3.4 (95% CI, 1.3–8.5) for diabetes diagnosed before or 
during the index pregnancy and 1.4 (95% CI, 0.9–2.2) for gestational diabetes. Compared 
with control mothers, mothers in both case groups also were somewhat more likely to report 
cocaine use and to have had a multiple gestation, and mothers in the any microtia case group 
were slightly more likely to report hypertension diagnosed before pregnancy. For the other 
putative vasoactive exposures, we observed no evidence of associations with an increased 
risk for microtia.
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We identified the specific birth defects observed in the 115 infants with microtia classified 
as multiple, and there was no clear pattern of birth defects according to diabetes status. Of 
the 14 diabetes-exposed cases, the multiple structural defects were as follows: OAVS and 
cardiac defects (3); OAVS, cardiac defects, and hydrocephaly (1); OAVS and cleft lip and 
palate (1); OAVS, sacral agenesis and cardiac defects (1); microtia, sacral agenesis, cardiac 
and central nervous system defects (1); microtia, cleft palate, cardiac defects, and limb 
deficiency (1); microtia, cardiac defects and either sacral agenesis, clubfeet, or hydrocephaly 
(3); and microtia and cardiac defects (3).
In our analysis, stratified by time to interview, the results were similar for mothers 
interviewed less than 1 year from their EDD and those interviewed 1 year or more from 
EDD.
Discussion
We investigated the association between risk of microtia and maternal vasoactive exposures 
and markers of vascular events to test the hypothesis that vascular disruption influences the 
development of this defect. Our findings do not support this hypothesis as only maternal 
diabetes diagnosed before or during the index pregnancy showed a strong and stable 
association with microtia suggesting instead that diabetic embryopathy may be involved. 
The diabetes association was observed for both overall and isolated microtia, although it was 
weaker for isolated microtia; these results are similar to those reported by Correa et al. 
(2008) using earlier data from the same source with approximately one-third fewer cases and 
controls and approximately half as many reports of maternal diabetes. Our OR of 7.2 for any 
microtia is similar to the OR of 6.3 reported by Werler et al. (2004b) in another case-control 
study. The relationship between maternal glycemic control and microtia in our study seemed 
to be hierarchical. We might expect that women with diabetes diagnosed during pregnancy 
would have the poorest glycemic control in early pregnancy under the assumption that they 
had pre-existing diabetes that remained undiagnosed until a first prenatal visit. Diabetes 
diagnosed during pregnancy was approximately 20 times more common in case (0.97%) 
than control mothers (0.05%). Because women with pre-existing diabetes have had the 
opportunity for treatment before pregnancy, their glycemic control in early pregnancy might 
be better than those diagnosed during pregnancy, but worse than gestational or nondiabetic 
women. This is consistent with our observation that the proportion of case mothers with pre-
existing diabetes (3.89%) was approximately seven times that of control mothers (0.59%), 
whereas the corresponding proportions for gestational diabetes (9.0% and 6.1%) reflected an 
aOR of only 1.4. If we take the hierarchical response one step further, we might also expect 
that, relative to nonobese women, obese women would have poorer glycemic control as a 
result of insulin resistance and their offspring would have a higher risk for microtia; this 
expectation is supported by an OR of 1.3 for obesity and microtia reported in another 
analysis of NBDPS data (Ma et al., 2010). As noted in the Methods section, we examined 
BMI as a potential confounder, but it did not meet our criterion for inclusion in the 
multivariable models.
In rat embryos, a critical level of glucose was necessary for malformations to occur, and 
above that threshold, the malformation rate increased exponentially as the glucose level 
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increased (Reece and Homko, 2000). Wang et al. (2002), in a clinical study, found the risk 
for OAVS was higher for maternal gestational diabetes (OR, 2.3; 95% CI, 1.0–4.8) than 
maternal pre-existing type 1 or 2 diabetes (OR, 1.5; 95% CI, 0.1–10.0) suggesting poorer 
glycemic control among women with gestational compared to those with pre-existing 
diabetes. We did not see a relationship between maternal diabetes and OAVS in this study; 
however, the clinical diagnosis of OAVS can be challenging and possibly subjective at the 
milder end of the spectrum. We likely under-ascertained OAVS when minor anomalies such 
as mild facial asymmetry/mandibular hypoplasia or facial nerve palsy were present. 
However, it seems doubtful that such under ascertainment would differ by maternal diabetes 
status because OAVS in association with maternal diabetes is not widely known. When 
Wang et al. (2002) examined microtia and other types of ear defects combined, ORs for 
gestational diabetes (OR, 1.2; 95% CI, 0.9–1.6) and pre-existing diabetes (OR, 0.9; 95% CI, 
0.5–1.8) approximated the null. In contrast, our more homogeneous case group of microtia 
but not other ear defects produced an aOR of 1.4 (95% CI, 0.9–2.0) for gestational diabetes 
and an aOR of 7.2 (95% CI, 3.9–13.1) for diabetes diagnosed before or during pregnancy.
Husain et al. (2008), in a study using data from a birth defects registry, noted that the risk 
factors identified for microtia differed from those identified for other defects with a 
purported vascular disruption mechanism, which lends support for a causal mechanism for 
microtia other than vascular disruption. Sadler and Rasmussen (2010) explored whether a 
vascular mechanism explained the development OAVS and found the experimental and 
clinical evidence inconclusive; they found stronger evidence to support a mechanism 
involving abnormal neural crest cell development. Hyperglycemia caused oxidative stress 
and inhibited the Pax 3 gene, which is responsible for neural crest cell development in 
rodent embryos (Zabihi and Loeken, 2010). However, nicotine has also been purported to 
cause oxidative stress, but both the present and another study observed no association 
between microtia and smoking (Mastroiacovo et al., 1995).
A number of animal and clinical studies have suggested that maternal alcohol use alters 
neural crest cell migration resulting in defects of structures derived from these cells (Sulik et 
al., 1988; Werler et al., 1991; Johnston and Bronsky, 1995; Sant'Anna and Tosello, 2006). If 
this alteration in neural crest cell migration were involved in the development of microtia, 
we would expect to see an association with alcohol in our study, but we did not (Table 1). 
However, the pathogenetic mechanisms that lead to abnormal ear development are not well 
understood, and abnormal neural crest cell migration may be only one causal component. 
Further, measurement error may have prevented our study from identifying an association 
with maternal alcohol use.
Our findings add to the evidence that diabetic embryopathy might also include microtia. 
Other embryopathies, such as fetal warfarin (Hall et al., 1980; Stevenson et al., 1980; 
Iturbe–Alessio et al., 1986; Bates et al., 2004) and rubella syndrome (Gregg, 1941; Webster, 
1998; De Santis et al., 2006; Morice et al., 2009), constitute well-defined phenotypes with 
distinct sets of affected structures. Diabetic embryopathy, on the other hand, is applied to a 
wide range of structural anomalies occurring among offspring of diabetic women, including 
cardiovascular, neural tube, musculoskeletal, gastrointestinal, and genitourinary defects and 
caudal regression sequence; infants often have multiple defects (Becerra et al., 1990; 
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Ferencz et al., 1990; Erickson, 1991; Ramos–Arroyo et al., 1992; Sheffield et al., 2002; Ray 
et al., 2004). Although the magnitude of the association with diabetes was higher for 
microtia in combination with other major structural defects, the corresponding 3.4-fold 
increased risk for isolated microtia suggests it alone might be another manifestation of the 
embryopathy.
This study had several limitations. The information on exposures was obtained via 
interviews of mothers conducted as long as 2 years after the EDD and consequently is 
subject to exposure recall error and misclassification. However, we observed little difference 
in our results when stratified by the time to interview, suggesting that recall by cases and 
controls was similar regardless of when the information was obtained. Also, with 
retrospective collection of exposure information, recall bias is a concern. If differential 
reporting of exposure information occurred between case and control mothers, we would 
expect control mothers to underreport medication use; the absence of associations for most 
exposures suggests this generally did not occur. For reporting of smoking and recreational 
drug use, both nondifferential and differential underreporting are possible and may have 
occurred in this study. For example, the number of exposures to cocaine and amphetamines 
reported by both case and control mothers was very small. Misclassification of the timing of 
medication exposures was possible, particularly for those used intermittently. However, the 
structured interview questions on illnesses and medication use likely improved accurate 
recall of exposure dates. Misclassification of the type of diabetes was also possible, 
especially for mothers who reported diabetes diagnosed during early pregnancy who may 
indeed have had gestational diabetes. However, the ORs for early pregnancy diabetes 
diagnosis were similar to those for pre-existing diabetes, which suggests our combining the 
two groups of women was appropriate. Many of the exposures we investigated, including 
diabetes, were reported by only small numbers of women making the results relatively 
unstable. In addition, although we considered potential confounders in our analyses, 
unidentified factors may have confounded our results. Finally, because the diagnostic 
information for cases was obtained via medical record review, the accuracy of these data is 
dependent on the thoroughness of the clinical evaluation, the completeness of 
documentation of the phenotype, and the appropriateness of assigned diagnostic codes used 
to ascertain the record. Although it is unlikely that these parameters would vary by maternal 
exposures for the studied defect, microtia, there could be an effect on the identification of 
additional major birth defects.
Our study also had strengths. Case and control ascertainment was population-based and 
from geographically diverse areas of the United States. The medical records of case infants 
were reviewed by a clinical geneticist and classified according to predefined, standardized 
criteria. Classification of medication exposures was also standardized by use of the Slone 
Drug Dictionary.
Our large, population-based, case-control study did not find associations between the 
occurrence of microtia and vasoactive exposures, but instead observed an association with 
maternal diabetes. Further investigation of the underlying causal pathways involved in 
diabetic embryopathy will help us better understand the risk factors for microtia.
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Table 1
Characteristics of Cases with Microtia (Any and Isolated) and Controls, National Birth 
Defects Prevention Study, 1997–2005
Any microtia (n = 421) N (%) Isolated microtia (n = 304) N (%) Controls (n = 6747) N (%)
Maternal age at delivery (years)
 <20 50 (12) 38 (13) 719 (11)
 20–29 212 (50) 147 (48) 3327 (49)
 30+ 159 (38) 119 (39) 2701 (40)
Maternal race
 Non-Hispanic white 155 (37) 101 (33) 4021 (60)
 Non-Hispanic black 12 (3) 7 (2) 767 (11)
 Hispanic 223 (53) 170 (56) 1497 (22)
 Other 28 (7) 23 (8) 433 (6)
 Missing 3 (1) 3 (1) 29 (<1)
Maternal education (years)
 <12 126 (30) 92 (30) 1130 (17)
 12 106 (25) 77 (25) 1652 (25)
 13+ 187 (44) 134 (44) 3916 (58)
 Missing 2 (1) 1 (<1) 49 (1)
Periconceptional folic acid use
 Yes 161 (38) 110 (36) 3429 (51)
 No 260 (62) 194 (64) 3318 (49)
Study site
 Arkansas 26 (6) 20 (7) 839 (12)
 California 104 (25) 79 (26) 851 (13)
 Georgia 23 (6) 17 (6) 733 (11)
 Iowa 23 (6) 13 (4) 759 (11)
 Massachusetts 39 (9) 26 (9) 856 (13)
 New Jersey 53 (13) 41 (14) 573 (9)
 New York 27 (6) 19 (6) 598 (9)
 North Carolina 10 (2) 8 (3) 397 (6)
 Texas 88 (21) 59 (19) 772 (11)
 Utah 28 (7) 22 (7) 369 (6)
Wanted to become pregnant
 Yes/did not care 295 (70) 221 (73) 4789 (71)
 No 64 (15) 37 (12) 668 (10)
 Missing 62 (15) 46 (15) 1290 (19)
Parity
 0 163 (39) 120 (40) 2709 (40)
 1+ 258 (61) 184 (61) 4031 (60)
 Missing 0 (0) 0 (0) 7 (<1)
Binge alcohol use (≥4 drinks/sitting)a
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Any microtia (n = 421) N (%) Isolated microtia (n = 304) N (%) Controls (n = 6747) N (%)
 Yes 47 (11) 33 (11) 814 (12)
 Alcohol use, but not binge 94 (22) 68 (22) 1629 (24)
 No alcohol use 276 (66) 201 (66) 4215 (63)
 Missing 4 (1) 2 (1) 89 (1)
Infant sex
 Male 242 (58) 181 (60) 3412 (51)
 Female 179 (43) 123 (41) 3330 (49)
 Other/missing 0 (0) 0 (0) 5 (<1)
Birth year
 1997 8 (2) 8 (3) 113 (2)
 1998 40 (10) 28 (9) 750 (11)
 1999 62 (15) 47 (16) 871 (13)
 2000 61 (15) 44 (15) 898 (13)
 2001 56 (13) 39 (13) 790 (12)
 2002 40 (10) 28 (9) 685 (10)
 2003 44 (11) 30 (10) 897 (13)
 2004 65 (15) 45 (15) 892 (13)
 2005 45 (11) 35 (12) 851 (13)
Pre-pregnancy BMI (kg/m2)
 Underweight (<18.5) 20 (5) 13 (4) 360 (5)
 Normal (18.5–<25) 203 (48) 145 (48) 3617 (54)
 Overweight (25–<30) 81 (19) 63 (21) 1454 (22)
 Obese (≥30) 74 (18) 50 (16) 1046 (16)
 Missing 43 (10) 33 (11) 270 (4)
Annual household income
 <$10,000 109 (26) 75 (25) 1080 (16)
 $10,000–50,000 189 (45) 140 (46) 2887 (43)
 >$50,000 90 (21) 63 (21) 2132 (32)
 Missing 33 (8) 26 (9) 648 (10)
Maternal birthplace
 United States 249 (59) 167 (55) 5412 (80)
 Outside United States 170 (41) 136 (45) 1290 (19)
 Missing 2 (<1) 1 (<1) 45 (1)
a
Use in 1 month before through month 3 of pregnancy. BMI, body mass index.
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